HC Wainwright & Co. Reiterates Buy on Corbus Pharmaceuticals, Maintains $35 Price Target
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Corbus Pharmaceuticals (NASDAQ:CRBP) with a Buy and maintains $35 price target.
Stocks · News reference
8-K filing — Corbus Pharmaceuticals Holdings, Inc. (CRBP)
Filed: 2026-09-14 AccNo: 0001193125-26-389829 Size: 25 MB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Corbus Pharmaceuticals Obesity Drug Avoids 'Depressive Effects'
Corbus Pharmaceuticals reports positive Phase 1b trial results for obesity drug CRB-913, demonstrating significant 12-week weight loss.
Market-Moving News for September 14th
GLW: -8% | Corning shares are trading lower after the company announced a $2 billion offering. ELMT: 49% | Elmet Group Lands $450M US Government Investment To Expand Tungsten Manufacturing, To Invest More Than $165M
Corbus Pharma Announces Topline Data From CANYON-1 Phase 1b Trial Of CRB-913 Demonstrating Statistically Significant And Clinically Meaningful Weight Loss In Obesity
CRB-913 demonstrated statistically significant and clinically meaningful mean weight loss of 5% at 60 mg after 12 weeks with no plateau observed CRB-913 was generally well tolerated with psychiatric adverse events